Download PDF
Semin intervent Radiol 2024; 41(01): 001-010
DOI: 10.1055/s-0043-1778657
Review Article

SBRT for Liver Tumors: What the Interventional Radiologist Needs to Know

Michael J. Gutman
1   Department of Radiation and Cellular Oncology, The University of Chicago Medicine, Chicago, Illinois
,
Lucas M. Serra
1   Department of Radiation and Cellular Oncology, The University of Chicago Medicine, Chicago, Illinois
,
Matthew Koshy
1   Department of Radiation and Cellular Oncology, The University of Chicago Medicine, Chicago, Illinois
,
Rohan R. Katipally
1   Department of Radiation and Cellular Oncology, The University of Chicago Medicine, Chicago, Illinois
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

This review summarizes the clinical evidence supporting the utilization of stereotactic body radiotherapy (SBRT) for liver tumors, including hepatocellular carcinoma, liver metastases, and cholangiocarcinoma. Emerging prospective evidence has demonstrated the benefit and low rates of toxicity across a broad range of clinical contexts. We provide an introduction for the interventional radiologist, with a discussion of underlying themes such as tumor dose–response, mitigation of liver toxicity, and the technical considerations relevant to performing liver SBRT. Ultimately, we recommend that SBRT should be routinely included in the armamentarium of locoregional therapies for liver malignancies, alongside those liver-directed therapies offered by interventional radiology.

Keywords

liver SBRT - stereotactic body radiotherapy - HCC SBRT - stereotactic ablative radiotherapy - interventional radiology


Publication History

Article published online:
14 March 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Blomgren H, Lax I, Näslund I, Svanström R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 1995; 34 (06) 861-870
    CrossrefPubMedGoogle Scholar
  • 2 Miften M, Vinogradskiy Y, Moiseenko V. et al. Radiation dose-volume effects for liver SBRT. Int J Radiat Oncol Biol Phys 2021; 110 (01) 196-205
    CrossrefPubMedGoogle Scholar
  • 3 Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002; 53 (04) 810-821
    CrossrefPubMedGoogle Scholar
  • 4 Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989; 62 (740) 679-694
    CrossrefPubMedGoogle Scholar
  • 5 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
    Google Scholar
  • 6 Gerum S, Jensen AD, Roeder F. Stereotactic body radiation therapy in patients with hepatocellular carcinoma: a mini-review. World J Gastrointest Oncol 2019; 11 (05) 367-376
    CrossrefPubMedGoogle Scholar
  • 7 Zeng ZC, Seong J, Yoon SM. et al. Consensus on stereotactic body radiation therapy for small-sized hepatocellular carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting. Liver Cancer 2017; 6 (04) 264-274
    CrossrefPubMedGoogle Scholar
  • 8 Wahl DR, Stenmark MH, Tao Y. et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol 2016; 34 (05) 452-459
    CrossrefPubMedGoogle Scholar
  • 9 Dobrzycka M, Spychalski P, Rostkowska O. et al. Stereotactic body radiation therapy for early-stage hepatocellular carcinoma - a systematic review on outcome. Acta Oncol 2019; 58 (12) 1706-1713
    CrossrefPubMedGoogle Scholar
  • 10 Hara K, Takeda A, Tsurugai Y. et al. Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation: a propensity score analysis. Hepatology 2019; 69 (06) 2533-2545
    CrossrefPubMedGoogle Scholar
  • 11 Lee J, Shin IS, Yoon WS, Koom WS, Rim CH. Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: meta-analyses and a systematic review. Radiother Oncol 2020; 145: 63-70
    CrossrefPubMedGoogle Scholar
  • 12 Wang L, Ke Q, Huang Q, Shao L, Chen J, Wu J. Stereotactic body radiotherapy versus radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia 2020; 37 (01) 1313-1321
    CrossrefPubMedGoogle Scholar
  • 13 Sanuki N, Takeda A, Kunieda E. Role of stereotactic body radiation therapy for hepatocellular carcinoma. World J Gastroenterol 2014; 20 (12) 3100-3111
    CrossrefPubMedGoogle Scholar
  • 14 Eriguchi T, Takeda A, Sanuki N. et al. Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system. Int J Radiat Oncol Biol Phys 2013; 85 (04) 1006-1011
    CrossrefPubMedGoogle Scholar
  • 15 Bujold A, Massey CA, Kim JJ. et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013; 31 (13) 1631-1639
    CrossrefPubMedGoogle Scholar
  • 16 Dawson LA, Winter KA, Knox JJ. et al. NRG/RTOG 1112: randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC). JCO 2023; 41 (04) 489-489
    CrossrefPubMedGoogle Scholar
  • 17 Ohri N, Tomé WA, Méndez Romero A. et al. Local control after stereotactic body radiation therapy for liver tumors. Int J Radiat Oncol Biol Phys 2021; 110 (01) 188-195
    CrossrefPubMedGoogle Scholar
  • 18 Garg R, Foley K, Movahedi B. et al. Outcomes after stereotactic body radiation therapy as a bridging modality to liver transplantation for hepatocellular carcinoma. Adv Radiat Oncol 2020; 6 (01) 100559
    CrossrefPubMedGoogle Scholar
  • 19 Kirichenko A, Uemura T, Liang Y. et al. Stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) with single photon emission computed tomography (SPECT) functional treatment planning in patients with advanced hepatic cirrhosis. Advances in Radiation Oncology 2023:101367. doi:10.1016/j.adro.2023.101367
    PubMedGoogle Scholar
  • 20 Wong TCL, Lee VHF, Law ALY. et al. Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant. Hepatology 2021; 74 (05) 2580-2594
    CrossrefPubMedGoogle Scholar
  • 21 Sapir E, Tao Y, Schipper MJ. et al. Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2018; 100 (01) 122-130
    CrossrefPubMedGoogle Scholar
  • 22 Shen PC, Chang WC, Lo CH. et al. Comparison of stereotactic body radiation therapy and transarterial chemoembolization for unresectable medium-sized hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2019; 105 (02) 307-318
    CrossrefPubMedGoogle Scholar
  • 23 Méndez Romero A, van der Holt B, Willemssen FEJA. et al. Transarterial chemoembolization with drug-eluting beads versus stereotactic body radiation therapy for hepatocellular carcinoma: outcomes from a multicenter, randomized, phase 2 trial (the TRENDY Trial). Int J Radiat Oncol Biol Phys 2023; 117 (01) 45-52
    CrossrefPubMedGoogle Scholar
  • 24 Comito T, Loi M, Franzese C. et al. Stereotactic radiotherapy after incomplete transarterial (chemo-) embolization (TAE) versus exclusive TAE or TACE for treatment of inoperable HCC: a phase III trial (NCT02323360). Curr Oncol 2022; 29 (11) 8802-8813
    CrossrefPubMedGoogle Scholar
  • 25 Bush DA, Volk M, Smith JC. et al. Proton beam radiotherapy versus transarterial chemoembolization for hepatocellular carcinoma: results of a randomized clinical trial. Cancer 2023; 129 (22) 3554-3563
    CrossrefPubMedGoogle Scholar
  • 26 Salem R, Gordon AC, Mouli S. et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2016; 151 (06) 1155-1163.e2
    CrossrefPubMedGoogle Scholar
  • 27 Brown AM, Kassab I, Massani M. et al. TACE versus TARE for patients with hepatocellular carcinoma: overall and individual patient level meta analysis. Cancer Med 2023; 12 (03) 2590-2599
    CrossrefPubMedGoogle Scholar
  • 28 Salem R, Johnson GE, Kim E. et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology 2021; 74 (05) 2342-2352
    CrossrefPubMedGoogle Scholar
  • 29 Salem R, Lewandowski RJ, Mulcahy MF. et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138 (01) 52-64
    CrossrefPubMedGoogle Scholar
  • 30 Finn RS, Qin S, Ikeda M. et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020; 382 (20) 1894-1905
    CrossrefPubMedGoogle Scholar
  • 31 Abou-Alfa GK, Lau G, Kudo M. et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 2022; 1 (08) DOI: 10.1056/EVIDoa2100070.
    CrossrefPubMedGoogle Scholar
  • 32 Juloori A, Katipally RR, Lemons JM. et al. Phase 1 randomized trial of stereotactic body radiation therapy followed by nivolumab plus ipilimumab or nivolumab alone in advanced/unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2023; 115 (01) 202-213
    CrossrefPubMedGoogle Scholar
  • 33 Ananthakrishnan A, Gogineni V, Saeian K. Epidemiology of primary and secondary liver cancers. Semin Intervent Radiol 2006; 23 (01) 47-63
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Ganesh K, Massagué J. Targeting metastatic cancer. Nat Med 2021; 27 (01) 34-44
    CrossrefPubMedGoogle Scholar
  • 35 Horn SR, Stoltzfus KC, Lehrer EJ. et al. Epidemiology of liver metastases. Cancer Epidemiol 2020; 67: 101760
    CrossrefPubMedGoogle Scholar
  • 36 Wang ZG, He ZY, Chen YY, Gao H, Du XL. Incidence and survival outcomes of secondary liver cancer: a Surveillance Epidemiology and End Results database analysis. Transl Cancer Res 2021; 10 (03) 1273-1283
    CrossrefPubMedGoogle Scholar
  • 37 Ayoub JP, Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Unknown primary tumors metastatic to liver. J Clin Oncol 1998; 16 (06) 2105-2112
    CrossrefPubMedGoogle Scholar
  • 38 Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994; 343 (8910): 1405-1410
    CrossrefPubMedGoogle Scholar
  • 39 Ohlsson B, Stenram U, Tranberg KG. Resection of colorectal liver metastases: 25-year experience. World J Surg 1998; 22 (03) 268-276 , discussion 276–277
    CrossrefPubMedGoogle Scholar
  • 40 Imai K, Adam R, Baba H. How to increase the resectability of initially unresectable colorectal liver metastases: a surgical perspective. Ann Gastroenterol Surg 2019; 3 (05) 476-486
    CrossrefPubMedGoogle Scholar
  • 41 Katipally RR, Pitroda SP, Juloori A, Chmura SJ, Weichselbaum RR. The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nat Rev Clin Oncol 2022; 19 (09) 585-599
    CrossrefPubMedGoogle Scholar
  • 42 Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995; 13 (01) 8-10
    CrossrefPubMedGoogle Scholar
  • 43 Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230 (03) 309-318 , discussion 318–321
    CrossrefPubMedGoogle Scholar
  • 44 Nordlinger B, Guiguet M, Vaillant JC. et al; Association Française de Chirurgie. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Cancer 1996; 77 (07) 1254-1262
    CrossrefPubMedGoogle Scholar
  • 45 Iwatsuki S, Dvorchik I, Madariaga JR. et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 1999; 189 (03) 291-299
    CrossrefPubMedGoogle Scholar
  • 46 Katipally RR, Martinez CA, Pugh SA. et al; with the S:CORT Consortium. Integrated clinical-molecular classification of colorectal liver metastases: a biomarker analysis of the phase 3 new EPOC randomized clinical trial. JAMA Oncol 2023; 9 (09) 1245-1254
    CrossrefPubMedGoogle Scholar
  • 47 Balachandran VP, Arora A, Gönen M. et al. A validated prognostic multigene expression assay for overall survival in resected colorectal cancer liver metastases. Clin Cancer Res 2016; 22 (10) 2575-2582
    CrossrefPubMedGoogle Scholar
  • 48 Wang Y, Lin HC, Huang MY. et al. The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases. Cancer Immunol Immunother 2018; 67 (03) 435-444
    CrossrefPubMedGoogle Scholar
  • 49 Spurr LF, Martinez CA, Katipally RR. et al. A proliferative subtype of colorectal liver metastases exhibits hypersensitivity to cytotoxic chemotherapy. NPJ Precis Oncol 2022; 6 (01) 72
    CrossrefPubMedGoogle Scholar
  • 50 Rusthoven KE, Kavanagh BD, Cardenes H. et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009; 27 (10) 1572-1578
    CrossrefPubMedGoogle Scholar
  • 51 Lee MT, Kim JJ, Dinniwell R. et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 2009; 27 (10) 1585-1591
    CrossrefPubMedGoogle Scholar
  • 52 Scorsetti M, Comito T, Tozzi A. et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol 2015; 141 (03) 543-553
    CrossrefPubMedGoogle Scholar
  • 53 Siva S, MacManus MP, Martin RF, Martin OA. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett 2015; 356 (01) 82-90
    CrossrefPubMedGoogle Scholar
  • 54 Grass GD, Krishna N, Kim S. The immune mechanisms of abscopal effect in radiation therapy. Curr Probl Cancer 2016; 40 (01) 10-24
    CrossrefPubMedGoogle Scholar
  • 55 Yilmaz MT, Elmali A, Yazici G. Abscopal effect, from myth to reality: from radiation oncologists' perspective. Cureus 2019; 11 (01) e3860
    PubMedGoogle Scholar
  • 56 Abuodeh Y, Venkat P, Kim S. Systematic review of case reports on the abscopal effect. Curr Probl Cancer 2016; 40 (01) 25-37
    CrossrefPubMedGoogle Scholar
  • 57 Wang L, Dou X, Chen S. et al. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell 2023; 41 (07) 1294-1308.e8
    CrossrefPubMedGoogle Scholar
  • 58 Dall'Olio FG, Marabelle A, Caramella C. et al. Tumour burden and efficacy of immune-checkpoint inhibitors. Nat Rev Clin Oncol 2022; 19 (02) 75-90
    CrossrefPubMedGoogle Scholar
  • 59 Nabet BY, Esfahani MS, Moding EJ. et al. Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition. Cell 2020; 183 (02) 363-376.e13
    CrossrefPubMedGoogle Scholar
  • 60 Chardin D, Paquet M, Schiappa R. et al. Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study. J Immunother Cancer 2020; 8 (02) e000645
    CrossrefPubMedGoogle Scholar
  • 61 Joseph RW, Elassaiss-Schaap J, Kefford R. et al. Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clin Cancer Res 2018; 24 (20) 4960-4967
    CrossrefPubMedGoogle Scholar
  • 62 Yu J, Green MD, Li S. et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med 2021; 27 (01) 152-164
    CrossrefPubMedGoogle Scholar
  • 63 Chang DT, Swaminath A, Kozak M. et al. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer 2011; 117 (17) 4060-4069
    CrossrefPubMedGoogle Scholar
  • 64 Andratschke N, Alheid H, Allgäuer M. et al. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer 2018; 18 (01) 283
    CrossrefPubMedGoogle Scholar
  • 65 Baker S, Jiang W, Mou B. et al. Progression-free survival and local control after SABR for up to 5 oligometastases: an analysis from the population-based phase 2 SABR-5 trial. Int J Radiat Oncol Biol Phys 2022; 114 (04) 617-626
    CrossrefPubMedGoogle Scholar
  • 66 Siva S, Bressel M, Mai T. et al; Stereotactic Ablative Fractionated Radiotherapy Versus Radiosurgery for Oligometastatic Neoplasia to the Lung (SAFRON) II Study Investigators. Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial. JAMA Oncol 2021; 7 (10) 1476-1485
    CrossrefPubMedGoogle Scholar
  • 67 Singh D, Chen Y, Hare MZ. et al. Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung. J Thorac Dis 2014; 6 (04) 369-374
    PubMedGoogle Scholar
  • 68 Brindley PJ, Bachini M, Ilyas SI. et al. Cholangiocarcinoma. Nat Rev Dis Primers 2021; 7 (01) 65
    CrossrefPubMedGoogle Scholar
  • 69 Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int 2019; 39 (Suppl. 01) 19-31
    CrossrefPubMedGoogle Scholar
  • 70 Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg 2014; 149 (06) 565-574
    CrossrefPubMedGoogle Scholar
  • 71 Lotfollahzadeh S, Hoilat GJ, Smith M, Recio-Boiles A, Babiker HM. Hepatobiliary Tract Cancer. In: StatPearls. StatPearls Publishing; 2023. Accessed November 2, 2023 at: http://www.ncbi.nlm.nih.gov/books/NBK441830/
    Google Scholar
  • 72 Wang N, Huang A, Kuang B, Xiao Y, Xiao Y, Ma H. Progress in radiotherapy for cholangiocarcinoma. Front Oncol 2022; 12: 868034
    CrossrefPubMedGoogle Scholar
  • 73 Jackson MW, Amini A, Jones BL, Rusthoven CG, Schefter TE, Goodman KA. Treatment selection and survival outcomes with and without radiation for unresectable, localized intrahepatic cholangiocarcinoma. Cancer J 2016; 22 (04) 237-242
    CrossrefPubMedGoogle Scholar
  • 74 Mahadevan A, Dagoglu N, Mancias J. et al. Stereotactic body radiotherapy (SBRT) for intrahepatic and hilar cholangiocarcinoma. J Cancer 2015; 6 (11) 1099-1104
    CrossrefPubMedGoogle Scholar
  • 75 Tse RV, Hawkins M, Lockwood G. et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008; 26 (04) 657-664
    CrossrefPubMedGoogle Scholar
  • 76 Kozak MM, Toesca DAS, von Eyben R, Pollom EL, Chang DT. Stereotactic body radiation therapy for cholangiocarcinoma: optimizing locoregional control with elective nodal irradiation. Adv Radiat Oncol 2019; 5 (01) 77-84
    CrossrefPubMedGoogle Scholar
  • 77 Lee J, Yoon WS, Koom WS, Rim CH. Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review. Strahlenther Onkol 2019; 195 (02) 93-102
    CrossrefPubMedGoogle Scholar
  • 78 Kim YI, Park JW, Kim BH. et al. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma. Radiat Oncol 2013; 8: 292
    CrossrefPubMedGoogle Scholar
  • 79 Tao R, Krishnan S, Bhosale PR. et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis. J Clin Oncol 2016; 34 (03) 219-226
    CrossrefPubMedGoogle Scholar
  • 80 Oliver PAK, Yewondwossen M, Summers C, Shaw C, Cwajna S, Syme A. Influence of intra- and interfraction motion on planning target volume margin in liver stereotactic body radiation therapy using breath hold. Adv Radiat Oncol 2020; 6 (01) 100610
    CrossrefPubMedGoogle Scholar
  • 81 Craig T, Xiao Y, McNulty S, Dawson LA. Insights from image guided radiation therapy credentialing for the NRG oncology RTOG 1112 Liver Stereotactic Body Radiation Therapy Trial. Pract Radiat Oncol 2023; 13 (03) 239-245
    CrossrefPubMedGoogle Scholar
  • 82 Guo B, Stephans K, Woody N, Antolak A, Moazzezi M, Xia P. Online verification of breath-hold reproducibility using kV-triggered imaging for liver stereotactic body radiation therapy. J Appl Clin Med Phys 2023; 24 (09) e14045
    CrossrefPubMedGoogle Scholar
  • 83 Witt JS, Rosenberg SA, Bassetti MF. MRI-guided adaptive radiotherapy for liver tumours: visualising the future. Lancet Oncol 2020; 21 (02) e74-e82
    CrossrefPubMedGoogle Scholar
  • 84 Boldrini L, Romano A, Mariani S. et al. MRI-guided stereotactic radiation therapy for hepatocellular carcinoma: a feasible and safe innovative treatment approach. J Cancer Res Clin Oncol 2021; 147 (07) 2057-2068
    CrossrefPubMedGoogle Scholar
  • 85 van Dams R, Wu TC, Kishan AU. et al. Ablative radiotherapy for liver tumors using stereotactic MRI-guidance: a prospective phase I trial. Radiother Oncol 2022; 170: 14-20
    CrossrefPubMedGoogle Scholar
  • 86 Rosenberg SA, Henke LE, Shaverdian N. et al. A multi-institutional experience of MR-guided liver stereotactic body radiation therapy. Adv Radiat Oncol 2018; 4 (01) 142-149
    CrossrefPubMedGoogle Scholar
  • 87 Yerak B. ViewRay Files for Bankruptcy With Plans to Sell Assets. The Wall Street Journal. Accessed December 26, 2023 at: https://www.wsj.com/articles/viewray-files-for-bankruptcy-plans-to-pursue-sale-62af0943 Published July 17, 2023
    PubMedGoogle Scholar
  • 88 Sanford NN, Pursley J, Noe B. et al. Protons versus photons for unresectable hepatocellular carcinoma: liver decompensation and overall survival. Int J Radiat Oncol Biol Phys 2019; 105 (01) 64-72
    CrossrefPubMedGoogle Scholar
  • 89 Rim CH, Kim HJ, Seong J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. Radiother Oncol 2019; 131: 135-144
    CrossrefPubMedGoogle Scholar
  • 90 Voglhuber T, Eitz KA, Oechsner M, Vogel MME, Combs SE. Analysis of using high-precision radiotherapy in the treatment of liver metastases regarding toxicity and survival. BMC Cancer 2021; 21 (01) 780
    CrossrefPubMedGoogle Scholar
  • 91 Pan CC, Kavanagh BD, Dawson LA. et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 2010; 76 (3, Suppl): S94-S100
    CrossrefPubMedGoogle Scholar
  • 92 Kim J, Jung Y. Radiation-induced liver disease: current understanding and future perspectives. Exp Mol Med 2017; 49 (07) e359-e359
    CrossrefPubMedGoogle Scholar
  • 93 Culleton S, Jiang H, Haddad CR. et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol 2014; 111 (03) 412-417
    CrossrefPubMedGoogle Scholar
  • 94 Lasley FD, Mannina EM, Johnson CS. et al. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Pract Radiat Oncol 2015; 5 (05) e443-e449
    CrossrefPubMedGoogle Scholar
  • 95 Lee P, Ma Y, Zacharias I. et al. Stereotactic body radiation therapy for hepatocellular carcinoma in patients with Child-Pugh B or C cirrhosis. Adv Radiat Oncol 2020; 5 (05) 889-896
    CrossrefPubMedGoogle Scholar
  • 96 Takahashi S, Kimura T, Kenjo M. et al. Case reports of portal vein thrombosis and bile duct stenosis after stereotactic body radiation therapy for hepatocellular carcinoma. Hepatol Res 2014; 44 (10) E273-E278
    CrossrefPubMedGoogle Scholar
  • 97 Toesca DAS, Osmundson EC, Eyben RV. et al. Central liver toxicity after SBRT: an expanded analysis and predictive nomogram. Radiother Oncol 2017; 122 (01) 130-136
    CrossrefPubMedGoogle Scholar